These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dendritic cells control CD4+CD25+ Treg cell suppressor function in vitro through juxtacrine delivery of IL-2. Kulhankova K; Rouse T; Nasr ME; Field EH PLoS One; 2012; 7(9):e43609. PubMed ID: 22984435 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. Gaudreau S; Guindi C; Ménard M; Besin G; Dupuis G; Amrani A J Immunol; 2007 Sep; 179(6):3638-47. PubMed ID: 17785799 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. Tarbell KV; Petit L; Zuo X; Toy P; Luo X; Mqadmi A; Yang H; Suthanthiran M; Mojsov S; Steinman RM J Exp Med; 2007 Jan; 204(1):191-201. PubMed ID: 17210729 [TBL] [Abstract][Full Text] [Related]
9. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Mukhopadhaya A; Hanafusa T; Jarchum I; Chen YG; Iwai Y; Serreze DV; Steinman RM; Tarbell KV; DiLorenzo TP Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6374-9. PubMed ID: 18430797 [TBL] [Abstract][Full Text] [Related]
10. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes. Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163 [TBL] [Abstract][Full Text] [Related]
11. Immature Dendritic Cell Therapy Confers Durable Immune Modulation in an Antigen-Dependent and Antigen-Independent Manner in Nonobese Diabetic Mice. Lo J; Xia CQ; Peng R; Clare-Salzler MJ J Immunol Res; 2018; 2018():5463879. PubMed ID: 29651443 [TBL] [Abstract][Full Text] [Related]
12. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. Grinberg-Bleyer Y; Saadoun D; Baeyens A; Billiard F; Goldstein JD; Grégoire S; Martin GH; Elhage R; Derian N; Carpentier W; Marodon G; Klatzmann D; Piaggio E; Salomon BL J Clin Invest; 2010 Dec; 120(12):4558-68. PubMed ID: 21099113 [TBL] [Abstract][Full Text] [Related]
13. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956 [TBL] [Abstract][Full Text] [Related]
14. Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. Chattopadhyay G; Shevach EM J Immunol; 2013 Dec; 191(12):5875-84. PubMed ID: 24218453 [TBL] [Abstract][Full Text] [Related]
15. CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. Price JD; Beauchamp NM; Rahir G; Zhao Y; Rieger CC; Lau-Kilby AW; Tarbell KV J Leukoc Biol; 2014 Feb; 95(2):325-36. PubMed ID: 24082013 [TBL] [Abstract][Full Text] [Related]
16. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. Tarbell KV; Yamazaki S; Olson K; Toy P; Steinman RM J Exp Med; 2004 Jun; 199(11):1467-77. PubMed ID: 15184500 [TBL] [Abstract][Full Text] [Related]
17. Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Besin G; Gaudreau S; Ménard M; Guindi C; Dupuis G; Amrani A Diabetes; 2008 Aug; 57(8):2107-17. PubMed ID: 18477807 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-1β produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: Implications for the timing of tolerizing immunotherapy. Bertin-Maghit S; Pang D; O'Sullivan B; Best S; Duggan E; Paul S; Thomas H; Kay TW; Harrison LC; Steptoe R; Thomas R Diabetes; 2011 Jan; 60(1):248-57. PubMed ID: 20980463 [TBL] [Abstract][Full Text] [Related]
19. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice. Manirarora JN; Wei CH J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409 [TBL] [Abstract][Full Text] [Related]
20. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]